SEC Form SC 13G/A filed by Myriad Genetics Inc. (Amendment)
$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $18.00 | Neutral | UBS |
| 12/9/2024 | $30.00 → $21.00 | Outperform → Market Perform | Leerink Partners |
| 9/19/2024 | $32.00 | Equal-Weight | Morgan Stanley |
| 8/28/2024 | $35.00 | Overweight | Wells Fargo |
| 6/27/2024 | $29.00 | Sector Outperform | Scotiabank |
| 6/3/2024 | $20.00 | Underperform | Jefferies |
| 5/8/2024 | $25.00 → $35.00 | Market Perform → Outperform | Leerink Partners |
| 12/21/2023 | $23.00 | Neutral | Piper Sandler |
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics." The study found that Prequel® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks' gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered beginning
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing. The "Know More Sooner" website provides the benefits and dispels the common myths of prenatal genetic testing, as well as where to get screened and what actions can be taken in the instance of a high-risk result. The site features real-life patient stories to illustrate how prenatal screening can help parents-to-be manage their pregnancies. "Many patients don't initially understand the importance of prenatal genetic screening, bu
SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology (also known as The Green Journal) and was highlighted in the American College of Obstetricians and Gynecologists (ACOG) Daily Bulletin. The study evaluated the change in genetic testing completion rate following the implementation of MyGeneHistory®, a guideline-based online patient screening tool, and a virtual patient education program
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
UBS initiated coverage of Myriad Genetics with a rating of Neutral and set a new price target of $18.00
Leerink Partners downgraded Myriad Genetics from Outperform to Market Perform and set a new price target of $21.00 from $30.00 previously
Morgan Stanley initiated coverage of Myriad Genetics with a rating of Equal-Weight and set a new price target of $32.00
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women's health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equity around, genetic testing throughout a woman's health journey including family planning, pregnancy management and hereditary cancer risk assessment. "We're thrilled to welcome Dallas
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombinat
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial ResultsThe company expects the following: Fourth quarter of 2024 total revenues to be between $209 million and $211 million, an increase of approximately 6% to 7% compared to fourth quarter of 2023. Full year 2024 total revenues to be between $836 million to $838 million, an increase of approximately 11% compared to full year 202
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverag